Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Histogen Inc HSTOQ

Healthcare Biotechnology
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI... see more

Recent & Breaking News (GREY:HSTOQ)

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

GlobeNewswire April 18, 2024

Histogen Announces Second Adjournment of Special Meeting of Stockholders

GlobeNewswire December 14, 2023

Histogen Announces Adjournment of Special Meeting of Stockholders

GlobeNewswire December 5, 2023

Histogen Announces Board Approval of Complete Liquidation and Dissolution

GlobeNewswire September 18, 2023

Histogen to Explore Strategic Alternatives

GlobeNewswire July 5, 2023

Histogen Reports First Quarter 2023 Results and Provides Business Update

GlobeNewswire May 11, 2023

Histogen Announces Online Publication in the Journal of Investigative Dermatology

GlobeNewswire April 20, 2023

Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University

GlobeNewswire April 3, 2023

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

GlobeNewswire March 16, 2023

Histogen Reports Year-End 2022 Results and Provides Business Update

GlobeNewswire March 9, 2023

Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 27, 2023

Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

GlobeNewswire January 3, 2023

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 10, 2022

Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 11, 2022

Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

GlobeNewswire July 27, 2022

Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire July 14, 2022

Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire July 12, 2022

Histogen Announces 1-for-20 Reverse Stock Split

GlobeNewswire June 1, 2022

Histogen to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 12, 2022